Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer

A. R. Jazieh; R. Komrokji; A. Gupta; S. Patil; D. Flora; M. Knapp; M. Issa; Nagla Fawzy Miligy Abdel Karim

doi:10.3109/07357900801944856

Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer

A. R. Jazieh, R. Komrokji, A. Gupta, S. Patil, D. Flora, M. Knapp, M. Issa, Nagla Fawzy Miligy Abdel Karim

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m² day 1 & 8 and Irinotecan 100 mg/m ² day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10) experienced partial response and 14 (70) experienced stable disease. The median time to disease progression was 4 months (95 CI: 2.86.6). The 1 year and 2 year survival rates were 36 and 27, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

Original language	English (US)
Pages (from-to)	932-936
Number of pages	5
Journal	Cancer Investigation
Volume	27
Issue number	9
DOIs	https://doi.org/10.3109/07357900801944856
State	Published - Oct 22 2009
Externally published	Yes

Keywords

Angiogenesis inhibitor
Chemotherapy
Thalidomide, non small cell lung cancer

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/07357900801944856

Cite this

@article{3faeb1622df04f99ac216ab2ddd95fe4,

title = "Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer",

abstract = "This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m2 day 1 & 8 and Irinotecan 100 mg/m 2 day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10) experienced partial response and 14 (70) experienced stable disease. The median time to disease progression was 4 months (95 CI: 2.86.6). The 1 year and 2 year survival rates were 36 and 27, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.",

keywords = "Angiogenesis inhibitor, Chemotherapy, Thalidomide, non small cell lung cancer",

author = "Jazieh, {A. R.} and R. Komrokji and A. Gupta and S. Patil and D. Flora and M. Knapp and M. Issa and {Abdel Karim}, {Nagla Fawzy Miligy}",

note = "Funding Information: Keywords: Thalidomide, non small cell lung cancer, chemotherapy, angiogenesis inhibitor This research is supported in part by Celgene and Pfizer Pharmaceutical. Correspondence to: Abdul Rahman Jazieh, MD, MPH Department of Oncology (Mail code 1777) P.O. Box 22490, Riyadh 11426 Kingdom of Saudi Arabia Tel: 966-1-2520088 Ext. 12764 Fax: 966-1-2520088 Ext. 14691 email: jazieha@ngha.med.sa.",

year = "2009",

month = oct,

day = "22",

doi = "10.3109/07357900801944856",

language = "English (US)",

volume = "27",

pages = "932--936",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer

AU - Jazieh, A. R.

AU - Komrokji, R.

AU - Gupta, A.

AU - Patil, S.

AU - Flora, D.

AU - Knapp, M.

AU - Issa, M.

AU - Abdel Karim, Nagla Fawzy Miligy

N1 - Funding Information: Keywords: Thalidomide, non small cell lung cancer, chemotherapy, angiogenesis inhibitor This research is supported in part by Celgene and Pfizer Pharmaceutical. Correspondence to: Abdul Rahman Jazieh, MD, MPH Department of Oncology (Mail code 1777) P.O. Box 22490, Riyadh 11426 Kingdom of Saudi Arabia Tel: 966-1-2520088 Ext. 12764 Fax: 966-1-2520088 Ext. 14691 email: jazieha@ngha.med.sa.

PY - 2009/10/22

Y1 - 2009/10/22

N2 - This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m2 day 1 & 8 and Irinotecan 100 mg/m 2 day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10) experienced partial response and 14 (70) experienced stable disease. The median time to disease progression was 4 months (95 CI: 2.86.6). The 1 year and 2 year survival rates were 36 and 27, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

AB - This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m2 day 1 & 8 and Irinotecan 100 mg/m 2 day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10) experienced partial response and 14 (70) experienced stable disease. The median time to disease progression was 4 months (95 CI: 2.86.6). The 1 year and 2 year survival rates were 36 and 27, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

KW - Angiogenesis inhibitor

KW - Chemotherapy

KW - Thalidomide, non small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=70350158634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350158634&partnerID=8YFLogxK

U2 - 10.3109/07357900801944856

DO - 10.3109/07357900801944856

M3 - Article

C2 - 19832041

AN - SCOPUS:70350158634

SN - 0735-7907

VL - 27

SP - 932

EP - 936

JO - Cancer Investigation

JF - Cancer Investigation

IS - 9

ER -

Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this